Concord Biotech Secures USFDA Approval for Tofacitinib Tablets, Targets USD 500 Million US Market
New Delhi: Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths, strengthening the company's presence in the highly competitive U.S. pharmaceutical market.
The approved Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), moderately to severely active ulcerative colitis (UC), and active polyarticular course juvenile idiopathic arthritis (pcJIA). The approval expands Concord Biotech's portfolio in the immunology and inflammatory disease segments.
According to the company, the combined U.S. market for Tofacitinib Tablets 5 mg and 10 mg is estimated at approximately US$ 500 million. The approval is expected to provide Concord Biotech with access to a sizeable market opportunity while supporting its efforts to broaden product offerings and accelerate growth across the U.S. and other international markets.
The company stated that the regulatory clearance aligns with its long-term growth strategy and is expected to further strengthen its position in the U.S. market. The approval was granted by the USFDA and covers both strengths of the product.
Concord Biotech informed stock exchanges that the development marks another milestone in its regulated market expansion strategy and reflects its continued focus on developing and commercialising complex pharmaceutical products for global markets.
According to Concord Biotech's regulatory filing, the USFDA approval for Tofacitinib Tablets, 5 mg and 10 mg, is in line with the company's growth strategy and will enhance its competitive position in the U.S. market.
The Ahmedabad-based pharmaceutical company said the approval will enable it to capitalise on attractive market opportunities while supporting its long-term business expansion plans in key international markets.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.